VKTX vs CGON vs MRK vs CRL

For growth investors, CG Oncology, Inc.

Common stock (CGON) is the stronger pick with 254. 7% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate Viking Therapeutics, Inc. (VKTX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Charles River Laboratories International, Inc.

is actually cheaper at 16. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Viking Therapeutics, Inc.

(VKTX) delivered a total return of +435. 3%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: VKTX returned +25. 8% versus CGON's +86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 48β versus Viking Therapeutics, Inc. 's 1. 61β — meaning VKTX is approximately 238% more volatile than MRK relative to the S&P 500. On balance sheet safety, Viking Therapeutics, Inc. (VKTX) carries a lower debt/equity ratio of 0% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CG Oncology, Inc.

Common stock (CGON) is pulling ahead at 254. 7% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Merck & Co. , Inc. grew EPS 8. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, CGON leads at 176. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -39. 9% for CG Oncology, Inc. Common stock — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -47. 2% for CGON. At the gross margin level — before operating expenses — MRK leads at 72. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Charles River Laboratories International, Inc.

(CRL) trades at 16. 4x forward P/E versus 21. 9x for Merck & Co. , Inc. — 5. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VKTX: 219. 0% to $100. 75.

In this comparison, MRK (2.

9% yield) pays a dividend. VKTX, CGON, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), 2. 9% yield, +166. 5% 10Y return). Viking Therapeutics, Inc. (VKTX) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +166. 5%, VKTX: +25. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VKTX is a small-cap quality compounder stock; CGON is a small-cap high-growth stock; MRK is a large-cap deep-value stock; CRL is a small-cap quality compounder stock. MRK pays a dividend while VKTX, CGON, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.